Ibalizumab-uiyk Biologic (TrogarzoTM) – 2018 Pipeline Review

Review of ibalizumab-uiyk (TrogarzoTM) a novel biologic for patients with multi-drug resistant HIV-1

Multi-drug resistant HIV (MDR-HIV) carries a greater risk of disease progression and leaves HIV patients with limited treatment options.

There are currently 10,000 people living with MDR-HIV in the United States, and due to this prevalence, it has become necessary to consider drug candidates with new mechanisms of action in order to offer a solution to the current drug resistance issue.

Ibalizumab-uiyk is a monoclonal antibody biologic developed for the treatment of patients with multi-drug resistant HIV-1 (MDR-HIV). This biologic, developed by TaiMed Biologics Inc., belongs to a new drug class called viral entry inhibitors, and has shown promising preliminary results in Phase III trials.

For our complete review of ibalizumab-uiyk :


 Executive Summary of Evaluation:

    Ibalizumab-uiyk (TaiMed Biologics Inc.)


Status Approved March 6, 2018
 PDUFA 4/3/2018
  Orphan Drug Designation 10/20/2014
  Breakthrough Therapy Designation 2/27/2015
  FDA Priority Review 6/30/17
  Patent Expiration 11/11/2031
Indications Multi-Drug Resistant HIV-1 Approved (BLA)
Efficacy Multi-Drug Resistant HIV-1 Efficacy reported in Phase III Trials


U.S. Food and Drug Administration FDA News Release https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599657.htm?utm_campaign=FDA%20approves%20new%20HIV%20treatment%20-%20Drug%20Information%20Update&utm_medium=email&utm_source=Eloqua  Accessed March 6, 2017.

NIH U.S. National Library of Medicine ClinicalTrails.gov  https://clinicaltrials.gov/ct2/home Accessed: February 26, 2018

“New Drug Benefits Patients with Multi-Drug Resistant HIV.” IDSA: Infectious Diseases Society of America, 28 Oct. 2016, www.idsociety.org/Press_Release_10_28_2016/. Accessed February 28, 2018.

Pharma Intelligence Center https://pharma.globaldata.com Accessed: February 19, 2018.

CDC Centers for Disease Control and Prevention. HIV/AIDS. https://www.cdc.gov/hiv/statistics/overview/ataglance.html Accessed: March 2, 2108.


Coauthored by: Kristen Ciampi, PharmD Candidate

Kristen is a sixth-year pharmacy student at the University of Rhode Island. Kristen is completing her studies through an advanced pharmacy practice rotation at RJ Health prior to graduating with a PharmD degree in May of 2018.


If this topic caught your interest, for a similar review of the rituximab biosimilar pipeline, please go to the summary blog for a link to log into and register to receive the full publication.